Press release – For immediate release – 5:45 pm CEST
Median Technologies to participate in several investor conferences in May and June 2025
Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, “Median” or the “Company”), manufacturer of eyonis™, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnosis, and a globally leading provider of AI-based image analyses and central imaging services for oncology drug developers, announced today that the Company will participate in upcoming investor conferences in May and June 2025.
- Forum Midcaps Gilbert Dupont – May 13, 2025 – Paris, France
- TP ICAP Midcap Annual Conference – May 15-16, 2025 – Paris, France
- Portzamparc Mid & Small Caps Conference – June 18-19, 2025 – Paris, France
Please get in touch through the respective conference booking systems, if you would like to request a one-on-one meeting with Median management at these events. Conferences are for institutional investors only.
Pioneering innovative imaging services and Software as Medical Devices, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median’s offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis®, an AI/ML tech-based suite of software as a medical device (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is also eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit